Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accelerated Drug Approvals: FDA May Involve NCI In Confirmatory Trials

Executive Summary

The National Cancer Institute could have a role in ensuring that confirmatory trials are conducted for cancer drugs that are given accelerated approval, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said

You may also be interested in...



“Underpowered” Cancer Trials Are Becoming “Major Problem” – FDA’s Pazdur

Cancer drug trials that are statistically "underpowered" because of their small size are becoming a "major problem," FDA Oncologic Drug Products Division Director Richard Pazdur, MD, told a joint American Society of Clinical Oncology/FDA workshop April 15 in Alexandria, Va

Accelerated Approval Needs Enforcement Mechanism For Confirmatory Trials

FDA needs to create an enforcement mechanism to ensure that companies with anticancer agents awarded accelerated approval complete confirmatory trials to show actual clinical benefit, the Oncologic Drugs Advisory Committee agreed

Cancer Drug Confirmatory Trials Should Be Initiated Early, FDA Says

FDA is urging sponsors of cancer drugs undergoing accelerated approval to initiate confirmatory studies early to avoid problems in completing trials often seen after approval

Latest News
See All
UsernamePublicRestriction

Register

PS041678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel